Esperança et al. 2026: Molecules Scoping Review—Ibogaine Therapeutic Potential, Cardiac Safety & SUD Translation

Definition

Definition: Monica Patrícia Esperança, Nelson G.M. Gomes, and Maria Graça Campos (2026) published the scoping review *Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives in the Treatment of Substance Use Disorders* in *Molecules* (doi: 10.3390/molecules31030545; *Molecules* 31(3):545). Authors synthesize preclinical and clinical literature on ibogaine for SUD with emphasis on withdrawal/craving signals, dose–response themes, and cardiac adverse events. They frame ibogaine’s multimodal neuropharmacology as scientifically interesting amid high global SUD burden, while stressing fragmented heterogeneous evidence, regulatory gaps, formulation/standardization limits, and unresolved cardiac safety—including hERG/IKr inhibition and QT/QTc prolongation involving ibogaine and long-lived noribogaine. This is a scoping review, not a late-phase efficacy proof, not a cure claim, and not validation of psychoactive IV ibogaine infusion. Ibogaine is U.S. Schedule I and not approved for any indication.

Short answer

Esperança and colleagues’ 2026 Molecules scoping review finds ibogaine scientifically intriguing for SUD but constrained by fragmented evidence and unresolved cardiac safety—hERG blockade and QTc risk included. A scoping review is not a cure and not proof of psychoactive IV ibogaine infusion. Schedule I; screen for cardiac risk first.

Why this paper matters

2024–2026 brought new human follow-ups, commentaries, and landscape papers. Families need a current scoping map that refuses to separate “hope” from “heart.” This article is that map. Next steps: /safety-and-screening → /apply. Pair with sequential-models psychiatry scoping (/blog/updated-scoping-sequential-ibogaine-psychiatry), thirty-year narrative (/blog/thirty-years-ibogaine-research-review), and CV teaching (/blog/ibogaine-cardiovascular-complications-review).

What was reviewed

Methods (plain language)

Scoping reviews chart the breadth of evidence rather than produce a single pooled effect size for “does it cure addiction?” Expect a structured synthesis of preclinical and clinical sources with explicit attention to where translation fails—especially cardiac risk and standardization. Readers should use this paper to update mental models of uncertainty, not to skip ECG.

Key findings / themes (no hype)

Themes aligned with the published abstract and cardiac-focused discussion:

• Approved SUD medications often hit narrow mechanisms; ibogaine’s multimodal profile (glutamatergic, dopaminergic, cortical/executive-network themes in the authors’ framing) is why researchers keep looking.
• Clinical translation remains blocked by heterogeneous data quality, regulatory patchiness, and formulation/standardization problems.
• Withdrawal and craving signals appear in parts of the literature—but evidence remains insufficient for definitive efficacy conclusions.
• Cardiac adverse events and hERG-linked repolarization delay are central translational constraints, compounded by noribogaine’s prolonged time course.
• Authors discuss a neurobiological “reset” hypothesis as a research framing—hypothesis ≠ proven consumer cure.
• Call to action: rigorous pharmacological, toxicological, and regulatory evaluation for safer standardized pathways.

Honest reading: “Therapeutic potential” in a title is an invitation to research discipline—not a marketing warranty.

How this 2026 scoping review fits with related research

Place Esperança et al. beside—not above—other honesty documents:

The review’s insistence on phytochemical validation and formulation standardization also matters for families: “ibogaine” on a label is not a uniform pharmaceutical product in gray-market settings. Purity, dose accuracy, and adulterants remain safety confounders even before hERG biology enters the room.

Cardiac safety deep dive (what families should keep)

Checklists: /blog/ibogaine-ecg-pre-infusion-checklist, /blog/ibogaine-telemetry-acls-monitoring, /blog/ibogaine-contraindications, /blog/ibogaine-pre-existing-heart-conditions.

Route honesty: scoping SUD literature ≠ IV infusion proof

Most human SUD ibogaine evidence remains oral or route-unspecified clinic observation. A 2026 scoping review that catalogs cardiac constraints does not magically become an efficacy RCT for psychoactive intravenous ibogaine. Oral + IV Mg protocols (e.g., MISTIC) still require oral≠IV labeling (/blog/stanford-ibogaine-mistic, /blog/ibogaine-oral-vs-iv). Entity: /what-is-ibogaine-infusion.

Limits and confounders

What this does NOT prove for IV ibogaine infusion

No cure claims.

Next steps

If a 2026 review’s “potential” language feels like permission, re-read the cardiac chapter. Then use /safety-and-screening and /apply only for physician-supervised IV ibogaine infusion exploration with screening literacy. Entity: /what-is-ibogaine-infusion.

FAQ

What is the Molecules 2026 ibogaine paper? A scoping review by Esperança, Gomes, and Campos on therapeutic potential, cardiac safety, and SUD translational perspectives (doi **10.3390/molecules31030545**).

Does it prove ibogaine cures addiction? No—scoping synthesis of fragmented evidence; no cure claims.

What cardiac mechanism do they emphasize? hERG/IKr inhibition with QT/QTc prolongation risk, including noribogaine’s contribution.

Is this about IV ibogaine infusion? No—it scopes SUD literature that is not IV infusion proof.

Are regulatory frameworks settled globally? No—authors highlight regulatory gaps and standardization limits.

Is ibogaine approved for medical use? No. Schedule I; not approved for any indication.

Should families still insist on ECG/telemetry? Yes.

Where should screening start? /safety-and-screening, then /apply if appropriate.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not approved for any indication. Our IV ibogaine programs in Mexico and Gabon are not approved U.S. clinics. Next steps: /safety-and-screening, then /apply.

Esperança et al. 2026 is a scoping review—not personal access, not a cure claim, and not psychoactive IV ibogaine efficacy proof.

Sources (selected)

1. Esperança M.P., Gomes N.G.M., Campos M.G. Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives… *Molecules*. 2026;31(3):545. doi: 10.3390/molecules31030545.
2. Litjens R.P.W., Brunt T.M. *Clin Toxicol*. 2016. doi: 10.3109/15563650.2016.1138226.
3. Alper K. et al. *Cardiovasc Toxicol*. 2016. doi: 10.1007/s12012-015-9311-5.
4. Brunt T.M. *Addiction*. 2026. doi: 10.1111/add.70319.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).